应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ONCY Oncolytics Biotech Inc
交易中 05-07 12:06:04 EDT
0.8957
-0.0243
-2.64%
最高
0.9300
最低
0.8810
成交量
49.58万
今开
0.9300
昨收
0.9200
日振幅
5.33%
总市值
1.04亿
流通市值
1.02亿
总股本
1.16亿
成交额
44.51万
换手率
0.43%
流通股本
1.14亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Oncolytics Biotech Inc:KRAS突变MSS型MCRC二线治疗反应持续时间较历史基准提升3-4倍
美股速递 · 05-04
Oncolytics Biotech Inc:KRAS突变MSS型MCRC二线治疗反应持续时间较历史基准提升3-4倍
Oncolytics Biotech Inc - Pelareorep联合疗法在二线KRAS突变MSS型结直肠癌中展现19.5个月中位缓解持续时间
美股速递 · 05-04
Oncolytics Biotech Inc - Pelareorep联合疗法在二线KRAS突变MSS型结直肠癌中展现19.5个月中位缓解持续时间
Oncolytics Biotech Inc 将开会讨论Pelareorep在二线及后线SCAC中的单臂关键研究
美股速递 · 04-06
Oncolytics Biotech Inc 将开会讨论Pelareorep在二线及后线SCAC中的单臂关键研究
Oncolytics Biotech Inc 定于2026年4月16日就Pelareorep用于肛门癌适应症召开FDA C类会议
美股速递 · 04-06
Oncolytics Biotech Inc 定于2026年4月16日就Pelareorep用于肛门癌适应症召开FDA C类会议
Oncolytics Biotech Inc将启动二线KRAS突变MSS型MCRC的对照研究,中期数据预计2026年底前公布
美股速递 · 02-04
Oncolytics Biotech Inc将启动二线KRAS突变MSS型MCRC的对照研究,中期数据预计2026年底前公布
Oncolytics Biotech® 旗下Pelareorep获FDA快速通道资格,用于治疗二线KRAS突变MSS转移性结直肠癌
美股速递 · 02-04
Oncolytics Biotech® 旗下Pelareorep获FDA快速通道资格,用于治疗二线KRAS突变MSS转移性结直肠癌
Oncolytics Biotech Inc.盘中异动 股价大涨5.49%
市场透视 · 01-21
Oncolytics Biotech Inc.盘中异动 股价大涨5.49%
Oncolytics Biotech Inc.盘中异动 临近收盘股价大涨5.00%报1.05美元
市场透视 · 01-15
Oncolytics Biotech Inc.盘中异动 临近收盘股价大涨5.00%报1.05美元
Oncolytics Biotech公布Goblet研究队列4最新临床数据,显示Pelareorep联合Atezolizumab在三线肛门癌治疗中的活性
美股速递 · 01-12
Oncolytics Biotech公布Goblet研究队列4最新临床数据,显示Pelareorep联合Atezolizumab在三线肛门癌治疗中的活性
Oncolytics Biotech® 发布支持 Pelareorep 在 KRAS 突变转移性结直肠癌中表现出良好疗效的转化数据
美股速递 · 2025-12-16
Oncolytics Biotech® 发布支持 Pelareorep 在 KRAS 突变转移性结直肠癌中表现出良好疗效的转化数据
Oncolytics Biotech® 与FDA达成一致,确定Pelareorep在一线胰腺癌中的关键研究设计
美股速递 · 2025-11-19
Oncolytics Biotech® 与FDA达成一致,确定Pelareorep在一线胰腺癌中的关键研究设计
加拿大皇家银行:维持Oncolytics Biotech(ONCY.US)评级,由优于大市调整至优于大市评级, 目标价由6.00美元调整至5.00美元。
金融界 · 2025-03-11
加拿大皇家银行:维持Oncolytics Biotech(ONCY.US)评级,由优于大市调整至优于大市评级, 目标价由6.00美元调整至5.00美元。
Oncolytics Biotech Inc.盘中异动 早盘大幅下跌5.59%
市场透视 · 2025-03-10
Oncolytics Biotech Inc.盘中异动 早盘大幅下跌5.59%
Oncolytics Biotech 2024财年GAAP每股收益(C$0.41)优于预期(C$0.42),$1590万现金余量可支撑至2025年第三季度
财报速递 · 2025-03-07
Oncolytics Biotech 2024财年GAAP每股收益(C$0.41)优于预期(C$0.42),$1590万现金余量可支撑至2025年第三季度
Oncolytics Biotech Inc.盘中异动 早盘股价大跌5.12%报0.700美元
市场透视 · 2025-03-06
Oncolytics Biotech Inc.盘中异动 早盘股价大跌5.12%报0.700美元
Oncolytics Biotech Inc.盘中异动 快速拉升6.03%报0.689美元
市场透视 · 2025-03-06
Oncolytics Biotech Inc.盘中异动 快速拉升6.03%报0.689美元
Oncolytics Biotech Inc.盘中异动 早盘股价大跌6.49%
市场透视 · 2025-03-04
Oncolytics Biotech Inc.盘中异动 早盘股价大跌6.49%
Oncolytics Biotech Inc.盘中异动 快速跳水5.18%报0.717美元
市场透视 · 2025-02-20
Oncolytics Biotech Inc.盘中异动 快速跳水5.18%报0.717美元
Oncolytics Biotech Inc.盘中异动 早盘急速下挫5.10%报0.737美元
市场透视 · 2025-02-10
Oncolytics Biotech Inc.盘中异动 早盘急速下挫5.10%报0.737美元
Oncolytics Biotech Inc.盘中异动 快速上涨5.23%报0.779美元
市场透视 · 2025-02-06
Oncolytics Biotech Inc.盘中异动 快速上涨5.23%报0.779美元
加载更多
公司概况
公司名称:
Oncolytics Biotech Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Oncolytics Biotech Inc.于1998年4月2日根据亚伯达法律以亚伯达有限责任公司的名字成立,并于2026年4月1日在内华达州重新注册成立。该公司是一家临床阶段的生物制药公司,正在开发pelareorep,这是一种静脉给药的免疫治疗药物,旨在选择性地在RAS突变的肿瘤中复制并激活免疫反应。该公司尚未实现盈利,需要额外融资以维持运营。
发行价格:
--
{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.8957,"timestamp":1778169915115,"preClose":0.92,"halted":0,"volume":495813,"delay":0,"changeRate":-0.026413043478260855,"floatShares":113999999,"shares":116128162,"eps":-0.300019,"marketStatus":"交易中","change":-0.0243,"latestTime":"05-07 12:06:04 EDT","open":0.93,"high":0.93,"low":0.881,"amount":445089.41626182,"amplitude":0.053261,"askPrice":0.8952,"askSize":600,"bidPrice":0.89,"bidSize":77,"shortable":3,"etf":0,"ttmEps":-0.300019,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778184000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.92,"preHourTrading":{"tag":"盘前","latestPrice":0.93,"preClose":0.92,"latestTime":"09:19 EDT","volume":8246,"amount":7734.196342599999,"timestamp":1778159979914,"change":0.01,"changeRate":0.01087,"amplitude":0.032609},"postHourTrading":{"tag":"盘后","latestPrice":0.9268,"preClose":0.92,"latestTime":"19:58 EDT","volume":4232,"amount":3992.3984,"timestamp":1778111922339,"change":0.0068,"changeRate":0.007391,"amplitude":0.052065},"volumeRatio":0.988706},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"1120765792","title":"Oncolytics Biotech Inc:KRAS突变MSS型MCRC二线治疗反应持续时间较历史基准提升3-4倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765792","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120765792?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:09","pubTimestamp":1777900185,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc最新研究数据显示,针对KRAS突变的微卫星稳定型转移性结直肠癌患者的二线治疗,其治疗反应持续时间取得显著突破。与历史基准的4-6个月相比,当前疗法使患者反应持续时间实现3-4倍的提升。\n这一突破性进展为晚期结直肠癌治疗领域注入新希望。尤其对于携带KRAS突变且微卫星状态稳定的患者群体,传统治疗方案效果有限,新数据预示着靶向治疗策略的重要进展。\n研究结果凸显了Oncolytics Biotech在肿瘤免疫治疗领域的创新实力。该公司专注于开发溶瘤病毒疗法,此次数据进一步验证了其技术平台在难治性癌症治疗中的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176989151","title":"Oncolytics Biotech Inc - Pelareorep联合疗法在二线KRAS突变MSS型结直肠癌中展现19.5个月中位缓解持续时间","url":"https://stock-news.laohu8.com/highlight/detail?id=1176989151","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176989151?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:08","pubTimestamp":1777900124,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc宣布,其核心候选药物pelareorep联合疗法在针对二线治疗KRAS突变、微卫星稳定(MSS)型转移性结直肠癌(mCRC)的临床试验中取得积极数据。研究结果显示,该联合治疗方案的中位缓解持续时间达到19.5个月,展现出持久的抗肿瘤活性。\n这一数据凸显了pelareorep在难治性结直肠癌患者群体中的治疗潜力,特别是针对KRAS突变这一常见且治疗挑战较大的亚型。较长的缓解持续时间可能为患者带来更显著的临床获益,也为后续临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100043313","title":"Oncolytics Biotech Inc 将开会讨论Pelareorep在二线及后线SCAC中的单臂关键研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1100043313","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100043313?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:02","pubTimestamp":1775480546,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc 宣布将召开会议,重点讨论其候选药物Pelareorep在二线及后线转移性结直肠腺癌(SCAC)患者中进行的单臂关键性研究。该研究旨在评估Pelareorep在这一难治患者群体中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177910860","title":"Oncolytics Biotech Inc 定于2026年4月16日就Pelareorep用于肛门癌适应症召开FDA C类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1177910860","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177910860?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:01","pubTimestamp":1775480480,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc (ONCY) 已安排于2026年4月16日与美国食品药品监督管理局(FDA)举行C类会议,会议核心议题将聚焦其候选药物Pelareorep在肛门癌领域的应用前景。此次会议旨在就相关研发路径与监管要求进行深入探讨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168061642","title":"Oncolytics Biotech Inc将启动二线KRAS突变MSS型MCRC的对照研究,中期数据预计2026年底前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1168061642","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168061642?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:52","pubTimestamp":1770213138,"startTime":"0","endTime":"0","summary":"生物技术公司Oncolytics Biotech Inc宣布,将针对二线KRAS突变、微卫星稳定(MSS)型转移性结直肠癌(MCRC)患者开展一项对照临床研究。该研究的初步中期数据预计最晚于2026年底前获得。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113488384","title":"Oncolytics Biotech® 旗下Pelareorep获FDA快速通道资格,用于治疗二线KRAS突变MSS转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1113488384","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113488384?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:50","pubTimestamp":1770213044,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc (ONCY) 宣布,其研发的候选药物Pelareorep已获得美国食品药品监督管理局(FDA)授予的快速通道资格,该资格针对的是二线治疗KRAS突变型微卫星稳定(MSS)转移性结直肠癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605484886","title":"Oncolytics Biotech Inc.盘中异动 股价大涨5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605484886","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605484886?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:34","pubTimestamp":1769006068,"startTime":"0","endTime":"0","summary":"北京时间2026年01月21日22时34分,Oncolytics Biotech Inc.股票出现异动,股价快速拉升5.49%。截至发稿,该股报1.045美元/股,成交量24.5644万股,换手率0.23%,振幅1.01%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体涨幅为0.05%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121223428a69cc092&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121223428a69cc092&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCWF","ONCY","BK4585","BK4588","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603678602","title":"Oncolytics Biotech Inc.盘中异动 临近收盘股价大涨5.00%报1.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603678602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603678602?lang=zh_cn&edition=full","pubTime":"2026-01-15 04:57","pubTimestamp":1768424273,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日04时57分,Oncolytics Biotech Inc.股票出现波动,股价快速上涨5.00%。截至发稿,该股报1.05美元/股,成交量61.9932万股,换手率0.58%,振幅7.79%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体跌幅为0.09%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011504575397a1d647&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011504575397a1d647&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONCY","ONCWF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176732363","title":"Oncolytics Biotech公布Goblet研究队列4最新临床数据,显示Pelareorep联合Atezolizumab在三线肛门癌治疗中的活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1176732363","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176732363?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:02","pubTimestamp":1768226544,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc近日公布了其Goblet研究中队列4的最新临床数据。该数据进一步证实了其核心候选药物Pelareorep与免疫检查点抑制剂Atezolizumab联合用药方案,在针对接受过三线治疗的肛门癌患者群体中,展现出令人鼓舞的治疗活性。\n此次数据更新为这一难治性癌症的治疗前景提供了新的见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124995891","title":"Oncolytics Biotech® 发布支持 Pelareorep 在 KRAS 突变转移性结直肠癌中表现出良好疗效的转化数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1124995891","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124995891?lang=zh_cn&edition=full","pubTime":"2025-12-16 22:02","pubTimestamp":1765893759,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech® 发布支持 Pelareorep 在 KRAS 突变转移性结直肠癌中的良好疗效及转化数据的消息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144869574","title":"Oncolytics Biotech® 与FDA达成一致,确定Pelareorep在一线胰腺癌中的关键研究设计","url":"https://stock-news.laohu8.com/highlight/detail?id=1144869574","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144869574?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:02","pubTimestamp":1763560935,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech® 与FDA达成一致,确定Pelareorep在一线胰腺癌中的关键研究设计","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518700012","title":"加拿大皇家银行:维持Oncolytics Biotech(ONCY.US)评级,由优于大市调整至优于大市评级, 目标价由6.00美元调整至5.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518700012","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518700012?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:52","pubTimestamp":1741625543,"startTime":"0","endTime":"0","summary":"加拿大皇家银行:维持Oncolytics Biotech(ONCY.US)评级,由优于大市调整至优于大市评级, 目标价由6.00美元调整至5.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11005248641243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518713012","title":"Oncolytics Biotech Inc.盘中异动 早盘大幅下跌5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518713012","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518713012?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:52","pubTimestamp":1741614720,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时52分,Oncolytics Biotech Inc.股票出现波动,股价快速下挫5.59%。截至发稿,该股报0.650美元/股,成交量2.8965万股,换手率0.04%,振幅5.78%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体涨幅为0.28%。其相关个股中,Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大,Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃,换手率分别为2809.66%、628.56%、126.92%,振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.,振幅分别为40.24%、28.59%、25.35%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021520198a2a262&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021520198a2a262&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCY","BK4139","ONCWF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109304519","title":"Oncolytics Biotech 2024财年GAAP每股收益(C$0.41)优于预期(C$0.42),$1590万现金余量可支撑至2025年第三季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1109304519","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109304519?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:12","pubTimestamp":1741349531,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech 报告季度每股亏损$,优于分析师预期的$,超出2.38%。这与去年同期持平。以上内容来自Benzinga Earnings专栏,原文如下:Oncolytics Biotech reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.38 percent. This is unchanged from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Oncolytics Biotech 2024财年GAAP每股收益(C$0.41)优于预期(C$0.42),$1590万现金余量可支撑至2025年第三季度","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517660251","title":"Oncolytics Biotech Inc.盘中异动 早盘股价大跌5.12%报0.700美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517660251","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517660251?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:44","pubTimestamp":1741272275,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时44分,Oncolytics Biotech Inc.股票出现异动,股价大幅跳水5.12%。截至发稿,该股报0.700美元/股,成交量5.4394万股,换手率0.07%,振幅3.48%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体跌幅为0.46%。其相关个股中,Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大,Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃,换手率分别为1276.82%、263.37%、58.71%,振幅较大的相关个股有Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Tonix Pharmaceuticals Holding Corp.,振幅分别为31.46%、30.53%、23.72%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224435abeb7b5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224435abeb7b5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCWF","BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517940666","title":"Oncolytics Biotech Inc.盘中异动 快速拉升6.03%报0.689美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517940666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517940666?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:51","pubTimestamp":1741197100,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时51分,Oncolytics Biotech Inc.股票出现波动,股价急速拉升6.03%。截至发稿,该股报0.689美元/股,成交量5.0539万股,换手率0.07%,振幅4.60%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体涨幅为1.24%。其相关个股中,Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为942.34%、304.49%、296.39%,振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.,振幅分别为82.59%、54.27%、47.22%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306015140989d727e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306015140989d727e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONCWF","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677970","title":"Oncolytics Biotech Inc.盘中异动 早盘股价大跌6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677970","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677970?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:31","pubTimestamp":1741098674,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时31分,Oncolytics Biotech Inc.股票出现波动,股价快速下挫6.49%。截至发稿,该股报0.620美元/股,成交量5.3039万股,换手率0.07%,振幅0.00%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体涨幅为0.31%。其相关个股中,Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Exicure, Inc.、Protagenic Therapeutics, Inc.涨幅较大,Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃,换手率分别为1047.69%、1024.96%、405.58%,振幅较大的相关个股有Orchestra Biomed Holdings, Inc.、Hoth Therapeutics, Inc.、Jasper Therapeutics, Inc.,振幅分别为5.85%、5.06%、4.84%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223114a25f03fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223114a25f03fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONCWF","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512806814","title":"Oncolytics Biotech Inc.盘中异动 快速跳水5.18%报0.717美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512806814","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512806814?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:36","pubTimestamp":1739986567,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时36分,Oncolytics Biotech Inc.股票出现异动,股价快速下跌5.18%。截至发稿,该股报0.717美元/股,成交量23.1895万股,换手率0.30%,振幅5.29%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体涨幅为0.45%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013607988b4f34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013607988b4f34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONCWF","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510866634","title":"Oncolytics Biotech Inc.盘中异动 早盘急速下挫5.10%报0.737美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510866634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510866634?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:06","pubTimestamp":1739200002,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日23时06分,Oncolytics Biotech Inc.股票出现波动,股价大幅下跌5.10%。截至发稿,该股报0.737美元/股,成交量11.9788万股,换手率0.16%,振幅6.44%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体涨幅为0.20%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210230642abc9ad8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210230642abc9ad8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCWF","ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509272987","title":"Oncolytics Biotech Inc.盘中异动 快速上涨5.23%报0.779美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509272987","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509272987?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:32","pubTimestamp":1738852321,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时32分,Oncolytics Biotech Inc.股票出现异动,股价大幅上涨5.23%。截至发稿,该股报0.779美元/股,成交量34.0492万股,换手率0.44%,振幅2.70%。Oncolytics Biotech Inc.股票所在的生物技术行业中,整体跌幅为0.02%。Oncolytics Biotech Inc.公司简介:Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223201a23bce41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223201a23bce41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCY","BK4139","ONCWF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":0.0563},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0997},{"period":"6month","weight":-0.098},{"period":"1year","weight":0.8039},{"period":"ytd","weight":0.0526}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Oncolytics Biotech Inc.于1998年4月2日根据亚伯达法律以亚伯达有限责任公司的名字成立,并于2026年4月1日在内华达州重新注册成立。该公司是一家临床阶段的生物制药公司,正在开发pelareorep,这是一种静脉给药的免疫治疗药物,旨在选择性地在RAS突变的肿瘤中复制并激活免疫反应。该公司尚未实现盈利,需要额外融资以维持运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.024604},{"month":5,"riseRate":0.375,"avgChangeRate":-0.002448},{"month":6,"riseRate":0.285714,"avgChangeRate":0.190573},{"month":7,"riseRate":0.5,"avgChangeRate":0.009647},{"month":8,"riseRate":0.25,"avgChangeRate":-0.092405},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Oncolytics Biotech Inc(ONCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Oncolytics Biotech Inc(ONCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}